Factors Associated With Precancerous Cervical Lesions in Human Immunodeficiency Virus-Infected Women: A Cross-Sectional Survey in Togo
- PMID: 38510316
- PMCID: PMC10953098
- DOI: 10.1177/11795549241234620
Factors Associated With Precancerous Cervical Lesions in Human Immunodeficiency Virus-Infected Women: A Cross-Sectional Survey in Togo
Abstract
Background: The burden of human immunodeficiency virus (HIV) in cervical cancer remains a major public health challenge in developing countries, like Togo. Precancerous lesions include all cellular abnormalities that have malignant potential that can develop into cancer. The objective of this study was to determine the prevalence and factors associated with precancerous cervical lesions in HIV-infected women in our context.
Methods: A cross-sectional descriptive study was carried out from November 31, 2022, to January 31, 2023, in an HIV care center in Lomé (Non-Governmental Organization Espoir Vie Togo [NGO EVT] Grand-Lomé-Togo).
Results: A total of 271 women were included with a mean age of 47.0 years and a standard deviation of 10.0 years, among whom 20.7% do not have any scholar education. Only 6.7% of them had previously performed cervical smear examinations. The prevalence of precancerous cervical lesions observed in people living with human immunodeficiency virus (PLHIV) was 11.4% with a 95% confidence interval (CI) of 5.0 to 15.4. Cytological abnormalities were marked by low-grade squamous intraepithelial lesion (LSIL) (5.1%), followed by the presence of atypical squamous cells of undetermined significance (ASCUS) (3.5%). A statistically significant association was found between parity and the presence of precancerous lesions (P = .014).
Conclusions: In this study, more than 1 out of 10 women living with HIV had precancerous cervical lesions, and parity was the factor associated. The implementation of a systematic screening program for precancerous cervical lesions and human papillomavirus (HPV) infection integrated into HIV care is necessary for early treatment.
Keywords: Cervix precancerous; Togo; factors; human immunodeficiency virus; women’s health.
© The Author(s) 2024.
Conflict of interest statement
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Similar articles
-
Risk Factors Associated With Human Papillomavirus Infection, Cervical Cancer, and Precancerous Lesions in Large-Scale Population Screening.Front Microbiol. 2022 Jun 30;13:914516. doi: 10.3389/fmicb.2022.914516. eCollection 2022. Front Microbiol. 2022. PMID: 35847094 Free PMC article.
-
Prevalence and correlates of cervical squamous intraepithelial lesions among HIV-infected and uninfected women in Central Kenya.Pan Afr Med J. 2021 May 18;39:44. doi: 10.11604/pamj.2021.39.44.27182. eCollection 2021. Pan Afr Med J. 2021. PMID: 34422167 Free PMC article.
-
Cervical Precancerous Lesions and Associated Factors Among Women Screened in Two Hospitals in the City of Douala, Cameroon.Cureus. 2023 Jul 17;15(7):e41993. doi: 10.7759/cureus.41993. eCollection 2023 Jul. Cureus. 2023. PMID: 37593257 Free PMC article.
-
High Prevalence of Cervical High-Grade Lesions and High-Risk Human Papillomavirus Infections in Women Living with HIV: A Case for Prioritizing Cervical Screening in This Vulnerable Group.Acta Cytol. 2022;66(6):496-506. doi: 10.1159/000525340. Epub 2022 Jun 27. Acta Cytol. 2022. PMID: 35760059
-
The clinical application of HPV E6/E7 mRNA testing in triaging women with atypical squamous cells of undetermined significance or low-grade squamous intra-epithelial lesion Pap smear: A meta-analysis.J Cancer Res Ther. 2017;13(4):613-620. doi: 10.4103/jcrt.JCRT_56_17. J Cancer Res Ther. 2017. PMID: 28901302 Review.
References
-
- Grellier N, Quéro L. [Cervical cancer: particularities in HIV patients]. Bull Cancer. 2014;101:1040-1047. - PubMed
-
- Pautier P, Morice P, De Crevoisier R. [HIV and uterine cervical cancer]. Bull Cancer. 2003;90:399-404. - PubMed
-
- Sung H, Ferlay J, Siegel RL, et al.. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-249. - PubMed
LinkOut - more resources
Full Text Sources